Protocid 20mg

Tablet

Pack Size : 14 Tablet x 1 Strip

Generics : Pantoprazole Sodium Sesquihydrate

Manufacturer : Acme Laboratories Ltd.

Best Price * TK 70.00

* Delivery will be done in Dhaka city only.

Alternative Product

Tablet Panoral - 20mg Eskayef Pharmaceuticals Ltd.

Tk 5.00

Tablet Pansec - 20mg Drug International Ltd.

Tk 5.05

Tablet Pantex - 20mg ACI Limited

Tk 5.02

Tablet Pantid 20 mg Tab Opsonin Pharma Ltd.

Tk 5.02

Tablet Pantid 40 mg Tab Opsonin Pharma Ltd.

Tk 7.90

More Information About - Protocid 20mg

Description

GenericName

PantoprazoleSodiumSesquihydrate

Precaution

Gastricmalignancyshouldberuledout.ConsiderZn++supplementationduringIVtherapyinpatientswhoarepronetoZn++deficiency.Pregnancy.MonitoringParametersMonitorMglevelspriortoinitiationandperiodicallyduringprolongeduse.LactationRiskSummaryPantoprazolehasbeendetectedinbreastmilkofanursingmotherafterasingle40mgoraldoseofpantoprazole.Therewerenoeffectsonthebreastfedinfant.Therearenodataonpantoprazoleeffectsonmilkproduction.Thedevelopmentalandhealthbenefitsofbreastfeedingshouldbeconsideredalongwiththemother?sclinicalneedforPROTONIXandanypotentialadverseeffectsonthebreastfedchildfrompantoprazoleorfromtheunderlyingmaternalcondition.

Indication

Pepticulcerdisease,H.pyloriinfection,Gastro-oesophagealrefluxdisease,Zollinger-Ellisonsyndrome,Oesophagitis,Acid-relateddyspepsia,NSAID-associatedulceration,ulcerresistanttoH2receptorantagonists,Gastrointestinal(GI)bleedingfromstress,Prophylaxisforacidaspirationsyndromeduringinductionofanaesthesia

ContraIndication

Concomitantusew/rilpivirine,atazanavirandnelfinavir.Lactation.

Dose

N/A

SideEffect

1-10%Headache(>4%),Abdominalpain(4%),Facialedema(<4%),Generalizededema(<2%),Chestpain(4%),Diarrhea(4%),Constipation(<4%),Pruritus(4%),Rash(4%),Flatulence(<4%),Hyperglycemia(1%),Nausea(1%),Vomiting(>4%),Photosensitivity(<2%)FrequencyNotDefinedAngioedema,Atrophicgastritis,Anteriorischemicopticneuropathy,Hepatocellulardamageleadingtohepaticfailure,Interstitialnephritis,Pancreatitis,Pancytopenia,Rhabdomyolysis,Riskofanaphylaxis,Stevens-Johnsonsyndrome,Fataltoxicepidermalnecrolysis,Erythemamultiforme

PregnancyCategory

Name:NotClassified

Description

FDAhasnotyetclassifiedthedrugintoaspecifiedpregnancycategory.

ModeofAction

Pantoprazoleisasubstitutedbenzimidazole,andalsoknownasPPIduetoitspropertytoblockthefinalstepofacidsecretionbyinhibitingH+/K+ATPaseenzymesystemingastricparietalcell.Bothbasalandstimulatedacidareinhibited.

Interaction

Increasedriskofdigoxin-inducedcardiotoxiceffects.Increasedriskofhypomagnesaemiaw/diuretics.MayincreaseINRandprothrombintimeofwarfarin.Mayincreaseserumconcentrationofmethotrexateandsaquinavir.Delayedabsorptionanddecreasedbioavailabilityw/sucralfate.Decreasedabsorptionofketoconazole,itraconazole.PotentiallyFatal:Maydecreaseserumlevelsandpharmacologicaleffectsofrilpivirine,atazanavirandnelfinavir.

PregnancyCategoryNote

PregnancyTherearenoadequateandwell-controlledstudiesinpregnantwomen;advisepregnantwomenofthepotentialriskoffetalharm;drugshouldbeusedduringpregnancyonlyifpotentialbenefitjustifiespotentialrisktofetusLactationPantoprazoleandmetabolitesareexcretedinmilkofrats.Pantoprazoleexcretioninhumanmilkhasbeendetectedinastudyofasinglenursingmotherafterasingle40mgoraldoseofpantoprazolesodium;clinicalrelevanceofthisfindingnotknown;manydrugsexcretedinhumanmilkhavepotentialforseriousadversereactionsinnursinginfants;basedonpotentialfortumorigenicityshownforpantoprazolesodiuminrodentcarcinogenicitystudies,adecisionshouldbemadewhethertodiscontinuenursingortodiscontinuedrug,takingintoaccountbenefitofdrugtomother

AdultDose

ErosiveEsophagitisAssociatedWithGERDTreatment:40mgPOqDayfor8-16weeksMaintenanceofhealing:40mgPOqDayAlternatively,40mgIVqDayfor7-10daysShort-termTreatmentofGERDOraltherapyinappropriateornotpossible:40mgIVinfusionover15minutesqDayfor7-10days;switchtoPOoncepatientabletoswallowZollinger-EllisonSyndrome40mgPOqDay;upto240mg/dayadministeredinsomepatients80mgIVinfusionq8-12hrupto7days;switchtoPOoncepatientabletoswallowPepticUlcerDiseaseDuodenalulcer:40mgPOqDayfor2-4weeksGastriculcer:40mgPOqDayfor4-8weeksElderly:Nodosageadjustmentneeded.Hepaticimpairment:Max:20mg/dayor40mgonalternatedays.

ChildDose

ErosiveEsophagitisAssociatedWithGERD<5years:Safetyandefficacynotestablished>5years15kgto<40kg:20mgPOqDayforupto8weeks40kgorgreater:40mgPOqDayforupto8weeks

RenalDose

Renalimpairment:Nodosageadjustmentneeded.

Administration

Controlled-release:Shouldbetakenonanemptystomach.Take1hrbeforemeals.Swallowwhole,donotchew/crush.Normalrelease:Maybetakenwithorwithoutfood.IVPreparationGERDwithahistoryoferosiveesophagitis15-mininfusion:Reconstitutewith10mLNS,THENfurtherdilutewith100mLD5W,NS,orLRtofinalconcentrationof0.4mg/mLZollinger-Ellisonsyndrome15-mininfusion:Reconstituteeachvialwith10mLNS,THENCombine2vialsandfurtherdilutewith80mLD5W,NS,orLRtototalvolumeof100mL(concentration0.8mg/mL)2-mininjection:Reconstitutewith10mLNStofinalconcentrationof4mg/mLIVAdministrationInfuseover15minnomorethan3mg/min(7mL/min)forGERDand6mg/min(7mL/min)forpathologichypersecretoryconditions

Disclaimer

The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.